Given that pomalidomide is expected to provide similar treatment efficacy against multiple myeloma while reducing the positive selection for high-risk TP53 clones, it is hypothesized that replacing lenalidomide with pomalidomide may decrease the risk of t-MN development in this context. This evidence concerns the gene TP53 and plasma cell myeloma.